Systemic inflammatory response syndrome treatment by powdered sorbent pheresis: The biologic-detoxification plasma filtration system

ASAIO Journal

Volumn 44, Issue 5, 1998, Pages

  Levy, Howard ^a,e   Ash, Stephen R ^b,c,d   Knab, William ^d   Steczko, Janusz ^d   Carr, David J ^d   Blake, Donald E ^d  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b PURDUE UNIVERSITY   (United States)

^c St Elizabeth Medical Center   (United States)

^d HemoCleanse Incorporated   (United States)

^e UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA; CHARCOAL; HEMODYNAMICS; LIVING SYSTEMS STUDIES; POWDERS; SILICA;

DETOXIFICATION PLASMA FILTRATION (DTPF) SYSTEMS; SORBENTS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS);

PATIENT TREATMENT;

CHARCOAL; CYTOKINE; HEPARIN; HYPERTENSIVE AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLASMA PROTEIN; SILICON DIOXIDE; SORBENT; TUMOR NECROSIS FACTOR ALPHA;

ABSORPTION; ADULT; AGED; APHERESIS; ARTICLE; CLINICAL ARTICLE; FEMALE; FILTER; FILTRATION; HUMAN; INFLAMMATION; MALE; MEMBRANE; SEPSIS; SYNDROME;

EID: 0032169965     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002480-199809000-00072     Document Type: Article

References (55)

1. Zeni F, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and a septic shock: a reassessment. Crit Care Med 25: 1095-1100, 1997.
2. Rietschel ET, Kirikae T, Schade FU, et al: Bacterial endotoxin: molecular relationship of structure to activity and function. FASEB J 8: 217-225, 1994.
3. Thijs LG, Hack CE: Time course of cytokine levels in sepsis. Intensive Care Med 21: S258-S263, 1995.
4. Epstein FH: Mechanism of disease. The role of interleukin-1 in disease. N Engl J Med 328: 106-113, 1993.
5. Hack CE, De Groot ER, Flet-Bersam JF, et al: Increased plasma level of interleukin-6 in sepsis. Blood 74: 1704-1710, 1989.
6. Dinarello CA: Controlling the production of interleukin-1 and tumor necrosis factor in disease. Nutrition 11: 695-697, 1995.
7. Matsushima K, Oppenheim JJ: Novel inflammatory cytokines inducible by IL-1 and TNF. Cytokine 1: 2-13, 1989.
8. Oppenheim JJ, Zachariae COC, Mukaida N, et al: Properties of the novel proinflammatory supergene "integrin" cytokine family. Ann Rev Immunol 9: 617-647, 1991.
9. Fukushima R, Alexander JW, Gianotti L, Ogle CK: Isolated pulmonary infection acts as a source of systemic tumor necrosis factor. Crit Care Med 22: 114-120, 1994.
10. Bone RC: The pathogenesis of sepsis. Ann Intern Med 115: 457-469, 1991.
11. Platzer C, Meisel CH, Vogt K, Platzer M, Volk H-D: Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating drugs. Int Immunol 7: 517-523, 1995.
12. Chernow B: New insights into the pathogenesis of circulatory shock. Pulm Perspect 13: 1-3, 1996.
13. Bone RC: Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 24: 163-172, 1996.
14. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24: 1125-1128, 1996.
15. Bone RC: Why sepsis trials fail. JAMA 276: 565-566, 1996.
16. Ash SR, Blake DE, Carr DJ, Harker KD: Push-pull sorbent-base pheresis for treatment of acute hepatic failure: the BioLogic-DTPF. ASAJO J 44: 129-139, 1998.
17. Ash SR, Blake DE, Carr DJ, Carter C, Howard T, Makowka L: Clinical effects of sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT). Int J Artif Organs 15: 151-161, 1992.
18. Ash SR: Hemodiabsorption in the treatment of acute hepatic failure. ASAJO J 40: 80-82, 1994.
19. Hughes RD, Pucknell A, Routley D, Langley PG, Wendon JA, Williams R: Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Int J Artif Organs 17: 657-662, 1994.
20. Ash SR: Hemodiabsorption in treatment of acute hepatic failure and chronic cirrhosis with ascites. Artif Organs 18: 355-362, 1994.
21. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ: Multiple Organ Dysfunction Score: a reliable descriptor of a complex clinical outcome. Crit Care Med 23: 1638-1652, 1995.
22. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 13: 818-829, 1985.
23. Bone RC, Balk RA, Fein AM, et al: A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, clinical trial. Crit Care Med 23: 994-1006, 1995.
24. Greenman RI, Schein RM, Martin MA, et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266: 1097-1102, 1991.
25. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 324: 429-436, 1991.
26. Dhainaut JF, Tenaillon A, Le Tulzo Y, et al: Platelet-activating factor receptor antagonist BN52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled multicenter clinical trial. Crit Care Med 22: 1720-1728, 1994.
27. Rustici A, Velucchi M, Faggioni R, et al: Molecular mapping and detoxification of the lipid. A binding site by synthetic peptides. Science 259: 361-365, 1993.
28. Christ WJ, Asano O, Robidoux ALC, et al: E5531, a pure endotoxin antagonist of high potency. Science 268: 80-83, 1995.
29. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome. Ann Intern Med 119: 771-778, 1993.
30. Blackwell TS, Christman JW: Sepsis and cytokines: current status. Br J Anesth 77: 110-117, 1996.
31. Damas P, Ledoux D, et al: Cytokine serum level during severe sepsis in human: IL-6 as a marker of severity. Ann Surg 215: 356-362, 1992.
32. Gardlund G, Sjolin J, et al: Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis 172: 296-301, 1995.
33. McAllister SK, Bland LA, et al: Patient cytokine response in transfusion-associated sepsis. Infect Immun 62: 2126-2128, 1994.
34. Bellomo R, Tipping P, Boyce N: Interleukin-6 and interleukin-8 extraction during continuous venovenous hemodiafiltration in septic acute renal failure. Ren Fail 17: 457-466, 1995.
35. Takakuwa T, Endo S, Nakae H, et al: Plasma levels of TNF-α, Endothelin-1 and thrombomodulin in patients with sepsis. Res Commun Chem Pathol Pharmacol 83: 261-269, 1994.
36. Pinsky MR: Clinical studies on cytokines in sepsis: role of serum cytokines in the development of multiple-systems organ failure. Nephrol Dial Transplant 9: 94-98, 1994.
37. Quezado ZMN, Banks SM, Natanson C: New strategies for combatting sepsis: the magic bullets missed the mark . . . but the search continues. Trends Biotechnol 13:56-63, 1995.
38. Davies MG, Hagen P-O: Systemic inflammatory response syndrome. Br J Surg 84: 920-935, 1997.
39. Goldfarb S, Golper TA: Proinflammatory cytokines and hemofiltration membranes. J Am Soc Nephrol 5: 228-232, 1994.
40. Braun N, Rosenfeld S, Giolai M, et al: Effect of continuous hemodiafiltration on IL-6, TNF-α, C3a, and TCC in patient with SIRS/ septic shock using two different membranes. Contrib Nephrol 116: 89-98, 1995.
41. Schetz M, Ferdinande P, Van den Berghe G, et al: Removal of pro-inflammatory cytokines with renal replacement therapy: sense or nonsense? Intensive Care Med 21: 169-176, 1995.
42. Staubach K-H, Rosenfeldt J-A, Veit O, Bruch H-P: Extracorporeal adsorption of endotoxin. Ther Apher 1: 67-74, 1997.
43. Riegel W, Ziegenfuss T, Rose S, Bauer M, Marzi I: Influence of venovenous hemofiltration on post-traumatic inflammation and hemodynamics. Contrib Nephrol 116: 56-61, 1995.
44. Groeneveld ABJ, Nauta JJP, Thijs LG: Peripheral vascular resistance in septic shock: its relation to outcome. Intensive Care Med 14: 141-147, 1988.
45. Bottoms G, Fessier J, Clark W, et al: Efficacy of convective removal of plasma mediators of endotoxic shock by continuous veno-venous hemofiltration. Shock 5: 149-154, 1996.
46. Hughes RD, Nagaki M, Keane H, Sheron N, Williams R: Artificial liver support in acute liver failure: A review of studies at King's. Artif Organs 6: 167-170, 1992.
47. Steczko J, Ash SR, Carr DJ, Blake DE: Cytokine and endotoxin removal from plasma by push-pull sorbent-based pheresis (the Biologic-DTPF System), 7th Annual International Conference on Sepsis, Washington, DC, 1997.
48. Steczko J, Ash S, Carr D. Blake D: Cytokine removal from plasma by push-pull sorbent-based pheresis (the Biologic-DTPF System). ASAIO J 43: 83A, 1997.
49. Ash SR, Steczko J, Carr DJ, Blake DE: Cytokine and bilirubin removal in acute hepatic failure by push-pull sorbent-based pheresis (the Biologic-DTPF System). Hepatology 26: 475A, 1997.
50. Steczko J, Ash SR, Levy H, Carr CJ, Blake DE: Cytokine removal from plasma of patients with sepsis by the Biologic-DTPF System. Hepatology 26: 604A, 1997.
51. Okarma TB, Blankenship J, Lin AT, Elkalay MA: Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome. United States Patent #5,437,861, August 1, 1995.
52. Hei DJ, Elkalay MA, Lin ATT, Kshirsagar B, Okarma TB, Blance HW: Removal of cytokines from HAS-containing solutions by adsorption onto silica. Biotech Bioengin 33: 1023-1040, 1994.
53. Okarma TB, Blankenship J, Lin AT, Elkalay MA: Removal of selected factors from whole blood or its components. United States Patent #5,523,096, June 4, 1996.
54. Weber C, Henne B, Loth F, Schoenhofen M, Falkenhagen D: development of cationically modified cellulose adsorbents for the removal of endotoxins. ASAIO J 41: M430-M434, 1995
55. Hanasawa K, Tani T, Kodama M: New approach to endotoxic and septic shock by means of polymyxin B immobilized fiber. Surg Gynecol Obstet 168: 323-330, 1989.